FI152074A7 - - Google Patents

Info

Publication number
FI152074A7
FI152074A7 FI1520/74A FI152074A FI152074A7 FI 152074 A7 FI152074 A7 FI 152074A7 FI 1520/74 A FI1520/74 A FI 1520/74A FI 152074 A FI152074 A FI 152074A FI 152074 A7 FI152074 A7 FI 152074A7
Authority
FI
Finland
Application number
FI1520/74A
Other languages
Finnish (fi)
Inventor
K G Fuxe
Original Assignee
Astra Laekemedel Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE7306960A external-priority patent/SE7306960L/xx
Application filed by Astra Laekemedel Ab filed Critical Astra Laekemedel Ab
Publication of FI152074A7 publication Critical patent/FI152074A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
FI1520/74A 1973-05-17 1974-05-16 FI152074A7 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7306960A SE7306960L (enExample) 1973-05-17

Publications (1)

Publication Number Publication Date
FI152074A7 true FI152074A7 (enExample) 1974-11-18

Family

ID=20317502

Family Applications (1)

Application Number Title Priority Date Filing Date
FI1520/74A FI152074A7 (enExample) 1973-05-17 1974-05-16

Country Status (7)

Country Link
US (1) US3961060A (enExample)
JP (1) JPS5029716A (enExample)
AU (1) AU6889274A (enExample)
DE (1) DE2423529A1 (enExample)
FI (1) FI152074A7 (enExample)
FR (1) FR2229412A1 (enExample)
NL (1) NL7406689A (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US5753712A (en) * 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
US5945424A (en) * 1998-07-31 1999-08-31 G & H Associates, Inc. Treatment of periodic limb movement syndrome
AU775102B2 (en) * 1999-09-13 2004-07-15 David M. Swope Composition and method for decreasing neurologic symptomatology
AU2001261022A1 (en) * 2000-05-24 2001-12-03 Eli Lilly And Company Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
IT1317049B1 (it) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
US20030092770A1 (en) * 2002-10-23 2003-05-15 Phil Skolnick Combination therapy for treatment of depression
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
JP2006518390A (ja) 2003-02-19 2006-08-10 エンダシア,インコーポレイテッド A1アデノシンレセプターアンタゴニスト
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
WO2004082624A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. Modafinil-based neurorehabilitation of impaired neurological function associated with injury
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
US8440685B1 (en) 2004-09-20 2013-05-14 MedDEV, Inc. Method for treatment of neurologic dysfunction
US7645766B1 (en) * 2004-09-20 2010-01-12 MedDEV, Inc. Method for treatment of depression and depressive mood disorders
US9364474B2 (en) 2004-09-20 2016-06-14 Meddev Inc. Method for treatment of neurologic dysfunction
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
US20150086481A1 (en) * 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
HK1219416A1 (zh) 2013-03-08 2017-04-07 Benjamin M. YU 以溶液或悬浮液的形式透皮传输咖啡因的方法和成分
CN106572986A (zh) 2014-03-10 2017-04-19 本杰明·M·余 用于经皮递送的方法和组合物
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
KR20230063451A (ko) * 2021-11-02 2023-05-09 연세대학교 산학협력단 세포예정괴사 관련 질병 치료제로서의 아포모르핀의 용도
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3646213A (en) * 1970-08-12 1972-02-29 Hoffmann La Roche Compositions and methods for treating depression with combinations of l-3 4-dihydroxyphenylalanine and a hydrazine

Also Published As

Publication number Publication date
FR2229412A1 (enExample) 1974-12-13
DE2423529A1 (de) 1974-12-05
NL7406689A (enExample) 1974-11-19
JPS5029716A (enExample) 1975-03-25
US3961060A (en) 1976-06-01
AU6889274A (en) 1975-11-20

Similar Documents

Publication Publication Date Title
AR201758A1 (enExample)
AU476761B2 (enExample)
AR201235Q (enExample)
AR201231Q (enExample)
AU474593B2 (enExample)
JPS5029716A (enExample)
AU465453B2 (enExample)
AU465434B2 (enExample)
AU450229B2 (enExample)
AU476714B2 (enExample)
AR201229Q (enExample)
AU472848B2 (enExample)
AU466283B2 (enExample)
AU476696B2 (enExample)
AR199451A1 (enExample)
AU476873B1 (enExample)
AU477823B2 (enExample)
AR200256A1 (enExample)
AR210729A1 (enExample)
AR196382A1 (enExample)
AR197627A1 (enExample)
AU477824B2 (enExample)
AR193950A1 (enExample)
AR200885A1 (enExample)
AU471461B2 (enExample)